454 related articles for article (PubMed ID: 29453313)
1. Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.
Singhal U; Wang Y; Henderson J; Niknafs YS; Qiao Y; Gursky A; Zaslavsky A; Chung JS; Smith DC; Karnes RJ; Chang SL; Feng FY; Palapattu GS; Taichman RS; Chinnaiyan AM; Tomlins SA; Morgan TM
Mol Cancer Res; 2018 Apr; 16(4):643-654. PubMed ID: 29453313
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.
Massard C; Oulhen M; Le Moulec S; Auger N; Foulon S; Abou-Lovergne A; Billiot F; Valent A; Marty V; Loriot Y; Fizazi K; Vielh P; Farace F
Oncotarget; 2016 Aug; 7(34):55069-55082. PubMed ID: 27391263
[TBL] [Abstract][Full Text] [Related]
3. Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients.
Cho WJ; Oliveira DS; Najy AJ; Mainetti LE; Aoun HD; Cher ML; Heath E; Kim HR; Bonfil RD
J Transl Med; 2016 Mar; 14():72. PubMed ID: 26975354
[TBL] [Abstract][Full Text] [Related]
4. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
[TBL] [Abstract][Full Text] [Related]
5. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
McDaniel AS; Ferraldeschi R; Krupa R; Landers M; Graf R; Louw J; Jendrisak A; Bales N; Marrinucci D; Zafeiriou Z; Flohr P; Sideris S; Crespo M; Figueiredo I; Mateo J; de Bono JS; Dittamore R; Tomlins SA; Attard G
BJU Int; 2017 Nov; 120(5B):E30-E44. PubMed ID: 27539393
[TBL] [Abstract][Full Text] [Related]
7. Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer.
Strati A; Zavridou M; Bournakis E; Mastoraki S; Lianidou E
Analyst; 2019 Nov; 144(22):6671-6680. PubMed ID: 31596277
[TBL] [Abstract][Full Text] [Related]
8. Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.
Chung JS; Wang Y; Henderson J; Singhal U; Qiao Y; Zaslavsky AB; Hovelson DH; Spratt DE; Reichert Z; Palapattu GS; Taichman RS; Tomlins SA; Morgan TM
Neoplasia; 2019 Aug; 21(8):802-809. PubMed ID: 31276932
[TBL] [Abstract][Full Text] [Related]
9. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
Sperger JM; Emamekhoo H; McKay RR; Stahlfeld CN; Singh A; Chen XE; Kwak L; Gilsdorf CS; Wolfe SK; Wei XX; Silver R; Zhang Z; Morris MJ; Bubley G; Feng FY; Scher HI; Rathkopf D; Dehm SM; Choueiri TK; Halabi S; Armstrong AJ; Wyatt AW; Taplin ME; Zhao SG; Lang JM
J Clin Oncol; 2021 Sep; 39(26):2926-2937. PubMed ID: 34197212
[TBL] [Abstract][Full Text] [Related]
10. Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Reichert ZR; Kasputis T; Nallandhighal S; Abusamra SM; Kasputis A; Haruray S; Wang Y; Williams S; Singhal U; Alva A; Cackowski FC; Caram MEV; Palmbos PL; Yentz SE; Smith DC; Alumkal JJ; Morgan TM
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008431
[TBL] [Abstract][Full Text] [Related]
11. Detection of AR-V7 in Liquid Biopsies of Castrate Resistant Prostate Cancer Patients: A Comparison of AR-V7 Analysis in Circulating Tumor Cells, Circulating Tumor RNA and Exosomes.
Nimir M; Ma Y; Jeffreys SA; Opperman T; Young F; Khan T; Ding P; Chua W; Balakrishnar B; Cooper A; De Souza P; Becker TM
Cells; 2019 Jul; 8(7):. PubMed ID: 31288377
[TBL] [Abstract][Full Text] [Related]
12. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.
Gupta S; Li J; Kemeny G; Bitting RL; Beaver J; Somarelli JA; Ware KE; Gregory S; Armstrong AJ
Clin Cancer Res; 2017 Mar; 23(5):1346-1357. PubMed ID: 27601596
[No Abstract] [Full Text] [Related]
13. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
Scher HI; Graf RP; Schreiber NA; McLaughlin B; Lu D; Louw J; Danila DC; Dugan L; Johnson A; Heller G; Fleisher M; Dittamore R
Eur Urol; 2017 Jun; 71(6):874-882. PubMed ID: 27979426
[TBL] [Abstract][Full Text] [Related]
14. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
Fernandez-Perez MP; Perez-Navarro E; Alonso-Gordoa T; Conteduca V; Font A; Vázquez-Estévez S; González-Del-Alba A; Wetterskog D; Antonarakis ES; Mellado B; Fernandez-Calvo O; Méndez-Vidal MJ; Climent MA; Duran I; Gallardo E; Rodriguez Sanchez A; Santander C; Sáez MI; Puente J; Tudela J; Martínez A; López-Andreo MJ; Padilla J; Lozano R; Hervas D; Luo J; de Giorgi U; Castellano D; Attard G; Grande E; Gonzalez-Billalabeitia E
Prostate; 2023 Mar; 83(4):376-384. PubMed ID: 36564933
[TBL] [Abstract][Full Text] [Related]
15. PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer.
Gupta S; Halabi S; Yang Q; Roy A; Tubbs A; Gore Y; George DJ; Nanus DM; Antonarakis ES; Danila DC; Szmulewitz RZ; Wenstrup R; Armstrong AJ
Clin Cancer Res; 2023 May; 29(10):1929-1937. PubMed ID: 36897758
[TBL] [Abstract][Full Text] [Related]
16. Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer.
Marín-Aguilera M; Reig Ò; Lozano JJ; Jiménez N; García-Recio S; Erill N; Gaba L; Tagliapietra A; Ortega V; Carrera G; Colomer A; Gascón P; Mellado B
Oncotarget; 2015 Apr; 6(12):10604-16. PubMed ID: 25871394
[TBL] [Abstract][Full Text] [Related]
17. An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer.
Miyamoto DT; Lee RJ; Kalinich M; LiCausi JA; Zheng Y; Chen T; Milner JD; Emmons E; Ho U; Broderick K; Silva E; Javaid S; Kwan TT; Hong X; Dahl DM; McGovern FJ; Efstathiou JA; Smith MR; Sequist LV; Kapur R; Wu CL; Stott SL; Ting DT; Giobbie-Hurder A; Toner M; Maheswaran S; Haber DA
Cancer Discov; 2018 Mar; 8(3):288-303. PubMed ID: 29301747
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer.
Kwan EM; Fettke H; Docanto MM; To SQ; Bukczynska P; Mant A; Pook D; Ng N; Graham LK; Mangiola S; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Horvath LG; Azad AA
Eur Urol Focus; 2021 Jan; 7(1):63-70. PubMed ID: 31103601
[TBL] [Abstract][Full Text] [Related]
19. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E
Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201
[TBL] [Abstract][Full Text] [Related]
20. Platelet-Coated Circulating Tumor Cells Are a Predictive Biomarker in Patients with Metastatic Castrate-Resistant Prostate Cancer.
Chai S; Matsumoto N; Storgard R; Peng CC; Aparicio A; Ormseth B; Rappard K; Cunningham K; Kolatkar A; Nevarez R; Tu KH; Hsu CJ; Malihi P; Corn P; Zurita A; Hicks J; Kuhn P; Ruiz-Velasco C
Mol Cancer Res; 2021 Dec; 19(12):2036-2045. PubMed ID: 34462330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]